The Unseen Cloud - A survey of vaping practices and the acquisition of vaping products within the United Kingdom.
This survey reported a higher prevalence of current cannabinoid-based vaping within the UK (5.5%) than previously reported in the US (2.0%).
Abstract
BACKGROUND Vaping of cannabinoid-based products and informal acquisition of vaping products were associated with the outbreak of E-cigarette or vaping associated lung injury (EVALI) in the United States (US). Current prevalence of cannabinoid-based vaping within the United Kingdom (UK) is not known and literature regarding the acquisition of vaping products is limited. AIM To estimate the prevalence of nicotine-based, nicotine-free and cannabinoid-based product vaping within the UK and to determine where vaping products are acquired. DESIGN AND METHODS A voluntary online survey of individuals aged 16 and over within the UK was conducted using a convenience sample. Data was collected on respondent demographics, smoking/vaping history, and acquisition of e-liquids/products. RESULTS 2478 responses were included. Median age 45 years (IQR 35-57). Prevalence of current vaping of nicotine-based e-liquids, nicotine-free e-liquids, and cannabinoid-based products was 14.4%, 11.2%, and 5.49% respectively. Current nicotine-based and nicotine-free vaping was most prevalent in 25-34 year olds (22.4% and 19.2% of respondents). Current cannabinoid-based vaping was most prevalent in 16-24 year olds. The most common 'ever' used cannabinoid-based products were cannabidiol (CBD) oil/cannabigerol (CBG) oil and cannabis leaves (4.8%). Specialist vaping stores were the most common source of 'ever' acquisition for all products. 36.8% and 40.5% of respondents who had ever vaped nicotine-based and nicotine-free e-liquids reported prior acquisition from informal sources. CONCLUSION This survey reported a higher prevalence of current cannabinoid-based vaping within the UK (5.5%) than previously reported in the US (2.0%). In addition to the informal acquisition of vaping products as demonstrated within the survey, these results highlight potential underestimation of the risk of EVALI within the UK.